Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

TRDA Purchases of Investments

Cash used to buy marketable securities and other investments.

Entrada Therapeutics, Inc.NASDAQ: TRDA

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments declines year over year

Q1 FY2026 purchases of investments of $11.83M (cash outflow) fell 85.2% year over year, behind the -82.6% change in trailing-twelve-month purchases of investments. Sequentially, it fell 36.0% from the prior quarter. Over 3 fiscal years it compounded at -13.9% a year.

Context

  • Purchases of investments amounted to 557.1% of revenue in FY2025, up 349.4 pp from a year earlier.
  • Purchases of investments grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -85.2% toward the trailing-twelve-month pace of -82.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11.83M-36.0% QoQ
Last fiscal yearDec 2025
-$141.61M-67.6% YoY
LTMMar 2026
-$73.42M-82.6% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-85.2%——
1 year-67.6%——
3-year CAGR-13.9%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(141.61M) USD
Year-over-year change
+67.6%

Purchases of Investments vs competitors

How TRDA compares with its peers on the latest reported figures

  • TRDA's LTM Mar 2026 purchases of investments of $73.42M is the 7th largest of the 11 companies compared; the peer median is $99.24M.
  • Its year-over-year change of -82.6% is the lowest of 8, against a peer median of -52.5%.
  • Purchases of investments amounts to 1279.5% of revenue for TRDA, versus a peer median of 15.9%.
TRDA Competitors Peer median
Purchases of Investments for TRDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$133.5B +92.9%+9.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$233.85M -43.9%-19.7%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$189.73M -42.6%-17.7%—
IMRXImmuneering CorporationLTM Mar 2026$160.59M —+20.9%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$100.45M -70.3%+34.7%275.2%
SGMTSagimet Biosciences Inc.LTM Mar 2026$98.04M -52.5%+37.1%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$73.42M -82.6%-13.9%1279.5%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$69.05M -79.2%-31.5%31.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$22.55M -56.0%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 ——0.0%
HUMAHumacyte, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding TRDA) $99.24M-52.5%+9.8%15.9%

Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Depreciation & Amortization1.12M1.9M2.84M3.77M4.1M
Deferred Income Tax00000
Stock-Based Compensation2.53M9.9M13.11M17.92M19.61M
Change in Working Capital(3.42M)(11.11M)136.32M(118.85M)(4.8M)
Accounts Receivables0002.2M2.5M
Inventory00000
Accounts Payables(715K)5.29M(2.81M)991K(1.8M)
Other Working Capital(2.71M)(16.4M)139.12M(122.04M)(5.5M)
Other Non-Cash Items74K151K(5.78M)(10.02M)(3.67M)
Operating Cash Flow(50.86M)(93.79M)139.8M(41.56M)(128.51M)
Capital Expenditures(4.58M)(2.89M)(5.61M)(3.16M)(1.04M)
Acquisitions (Net)00000
Purchases of Investments0(221.98M)(407.21M)(437.72M)(141.61M)
Sales of Investments076.21M274.43M413.08M259.46M
Other Investing Activities00000
Investing Cash Flow(4.58M)(148.65M)(138.4M)(27.8M)116.81M
Debt Repayment00000
Common Stock Issued190.69M479K19.41M99.61M887K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities939K01.63M3.36M0
Financing Cash Flow307.46M479K21.04M102.96M887K
Effect of Forex Changes0(3.95M)000
Net Change in Cash252.02M(245.91M)22.45M33.61M(10.82M)
Free Cash Flow(55.44M)(96.67M)134.19M(44.72M)(129.55M)

Entrada Therapeutics, Inc.

NASDAQ:TRDA

Intrinsic Alpha fair value

Locked

Current Price

$5.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.